Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLR2037 in metastatic prostate cancer
NCT07468396Phase 1Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Oct 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GLR2037 in prostate cancer (PCa), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Adverse Events, Dose Limiting Toxicity at 28 days and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
GLR2037
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07468396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468396.